Astex terminates epigenetics collaboration with GSK

Astex Pharmaceuticals ($ASTX) says it has decided to hand over the epigenetics program SuperGen was partnered on with GlaxoSmithKline ($GSK) following its merger with the biotech company. SuperGen partnered with GSK back in 2009, but the program failed to make the cut during a pipeline review of the companies' combined assets. "The decision to transfer the Climb epigenetic program to GSK was based on our assessment of internal resources and discussions with GSK," said Harren Jhoti, president of Astex. Release